RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to show no change in quarterly revenue when it reports results on March 4 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 77 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $58.00, about 0% above its last closing price of $57.98
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.89 | -0.93 | -0.65 | Beat | 30.2 |
Jun. 30 2025 | -0.62 | -0.64 | -0.65 | Missed | -1.2 |
Mar. 31 2025 | -1.09 | -1.08 | -0.64 | Beat | 40.7 |
Dec. 31 2024 | -2.50 | -2.98 | -9.12 | Missed | -206.5 |
Sep. 30 2024 | -4.57 | -4.51 | -3.76 | Beat | 16.7 |
Jun. 30 2024 | -5.78 | -5.76 | -5.68 | Beat | 1.4 |
Mar. 31 2024 | -6.41 | -6.47 | -6.32 | Beat | 2.3 |
Dec. 31 2023 | -6.86 | -6.87 | -6.40 | Beat | 6.8 |
This summary was machine generated March 2 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)